Trials in Los Angeles, California
Here are the top 10 medical studies for colorectal cancer in Los Angeles, California
Popular Filters
Phase 3 Trials
Small Molecule Kinase Inhibitor
Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.
Small Molecule Drug
Sotorasib + Panitumumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
Chemotherapy Tailored by ctDNA Status for Colon Cancer
Recruiting1 awardPhase 2 & 3
Los Angeles, California
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Kinase Inhibitor
XL092 + Atezolizumab vs Regorafenib for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
Checkpoint Inhibitor
Nivolumab-relatlimab Combo for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Trials With No Placebo
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Monoclonal Antibodies
NIS793 + Standard Therapy for Colorectal Cancer
Recruiting1 awardPhase 2
Los Angeles, California
This trial will compare the standard of care for second line treatment of metastatic colorectal cancer (mCRC) against different combinations of NIS793 and other investigational drugs. The goal is to see if this new approach is more effective and has fewer side effects.
PI3K Inhibitor
Targeted Therapies + Immunotherapy for Colorectal Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing the safety and effectiveness of drugs that either target cancer cells directly or help the immune system fight cancer. It focuses on patients with advanced colorectal cancer whose tumors have certain biomarkers. The goal is to see if these treatments work better for these specific patients.
Monoclonal Antibodies
NGM707 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Behavioural Intervention
Educational Intervention for Cancer Knowledge
Recruiting1 award6 criteria
Duarte, California
This trial studies a web-based cancer education tool called HOPE-Genomics. The tool provides patients with information about genomic testing and their own genomic test results. The goal is to improve patient's genomic knowledge and quality of patient-centered care.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.